Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 15/20 | 1.00 |
| ▸ | NR4A1 | P22736 | 3/20 | 1.00 |
| ▸ | NR4A3 | Q92570 | 3/20 | 1.00 |
| ▸ | RXRA | P19793 | 8/20 | 0.72 |
| ▸ | RXRB | P28702 | 7/20 | 0.72 |
| ▸ | RXRG | P48443 | 4/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.72 |
| ▸ | C5 | P01031 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.72 |
| ▸ | DRD2 | P14416 | 1/20 | 0.72 |
| ▸ | HPGD | P15428 | 1/20 | 0.72 |
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.72 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.72 |
| ▸ | HTR2A | P28223 | 1/20 | 0.72 |
| ▸ | HTR2C | P28335 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8152974 | 0.91 | NR4A2 (0.83) | NR4A2NR4A1NR4A3RXRARXRB | |
| SCHEMBL8146050 | 0.91 | NR4A2 (0.83) | NR4A2NR4A1NR4A3RXRARXRB | |
| SCHEMBL9455578 | 0.87 | NR4A2 (0.77) | NR4A2NR4A1NR4A3RXRARXRB | |
| SCHEMBL5734304 | 0.87 | NR4A2 (0.75) | NR4A2NR4A1NR4A3RXRARXRB | |
| SCHEMBL5732158 | 0.87 | NR4A2 (0.75) | NR4A2NR4A1NR4A3RXRARXRB | |
| SCHEMBL5763378 | 0.87 | NR4A2 (0.75) | NR4A2NR4A1NR4A3RXRARXRB | |
| SCHEMBL7500434 | 0.87 | NR4A2 (0.75) | NR4A2NR4A1NR4A3RXRARXRB | |
| Oxaprozin SCHEMBL3286 | 0.84 | RXRA (1.00) | NR4A2NR4A1NR4A3RXRARXRB | |
| Oxaprozin SCHEMBL8191237 | 0.84 | RXRA (1.00) | NR4A2NR4A1NR4A3RXRARXRB | |
| Oxaprozin SCHEMBL3849972 | 0.84 | RXRA (1.00) | NR4A2NR4A1NR4A3RXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060251689-A1 | Treatment or prevention of pruritus | ASTION DEVELOPMENT A/S | 2006-11-09 | — | — | US | claimed |
| US-20060229347-A1 | Treatment of eczemas | ASTION DEVELOPMENT A/S | 2006-10-12 | — | — | US | claimed |
| WO-2006102898-A2 | OXAPROZIN OR A CLOSELY RELATED COMPOUND FOR THE TREATMENT OF ECZEMA | ASTION PHARMA A/S (DK) | 2006-10-05 | — | — | WO | claimed |
| WO-2006102899-A2 | OXAPROZIN OR CLOSELY RELATED COMPOUND FOR THE TREATMENT AND PREVENTION OF | ASTION PHARMA A/S (DK) | 2006-10-05 | — | — | WO | claimed |
| WO-2006102900-A1 | DERMATOLOGICAL COMPOSITIONS AND SALTS FOR THE TREATMENT OF DERMATOLOGICAL DISEASES | ASTION PHARMA A/S (DK) | 2006-10-05 | — | — | WO | claimed |
| US-20060222671-A1 | Dermatological compositions and salts for the treatment of dermatological diseases | ASTION DEVELOPMENT A/S | 2006-10-05 | — | — | US | claimed |
| EP-1707200-A1 | Dermatological compositions comprising oxaprozin or a closely related compound for the treatment of dermatological diseases | Astion Development A/S (DK) | 2006-10-04 | — | — | EP | claimed |
| EP-1707201-A1 | Oxaprozin or a closely related compound for the treatment of eczema | Astion Development A/S (DK) | 2006-10-04 | — | — | EP | claimed |
| EP-1707199-A1 | Oxaprozin or closely related compound for the treatment and prevention of pruritus | Astion Development A/S (DK) | 2006-10-04 | — | — | EP | claimed |
| US-20060251689-A1 | Treatment or prevention of pruritus | ASTION DEVELOPMENT A/S | 2006-11-09 | — | — | US | disclosed |
| US-20060229347-A1 | Treatment of eczemas | ASTION DEVELOPMENT A/S | 2006-10-12 | — | — | US | disclosed |
| WO-2006102899-A2 | OXAPROZIN OR CLOSELY RELATED COMPOUND FOR THE TREATMENT AND PREVENTION OF | ASTION PHARMA A/S (DK) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006102898-A2 | OXAPROZIN OR A CLOSELY RELATED COMPOUND FOR THE TREATMENT OF ECZEMA | ASTION PHARMA A/S (DK) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006102900-A1 | DERMATOLOGICAL COMPOSITIONS AND SALTS FOR THE TREATMENT OF DERMATOLOGICAL DISEASES | ASTION PHARMA A/S (DK) | 2006-10-05 | — | — | WO | disclosed |
| US-20060222671-A1 | Dermatological compositions and salts for the treatment of dermatological diseases | ASTION DEVELOPMENT A/S | 2006-10-05 | — | — | US | disclosed |
| EP-1707200-A1 | Dermatological compositions comprising oxaprozin or a closely related compound for the treatment of dermatological diseases | Astion Development A/S (DK) | 2006-10-04 | — | — | EP | disclosed |
| EP-1707201-A1 | Oxaprozin or a closely related compound for the treatment of eczema | Astion Development A/S (DK) | 2006-10-04 | — | — | EP | disclosed |
| EP-1707199-A1 | Oxaprozin or closely related compound for the treatment and prevention of pruritus | Astion Development A/S (DK) | 2006-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229347-A1 | Treatment of eczemas | ZAP70, SYK, LCK | NR4A2 1164/4885NR4A1 2226/4885NR4A3 1044/4885 |
| US-20060251689-A1 | Treatment or prevention of pruritus | ITCH, TSLP, HRH4 | NR4A2 1009/4885NR4A1 2312/4885NR4A3 815/4885 |
| US-20060222671-A1 | Dermatological compositions and salts for the treatment of dermatological diseases | ZAP70, SYK, LCK | NR4A2 1772/4885NR4A1 2398/4885NR4A3 1485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.